Department of Pharmacognosy, College of Pharmacy, Hawler Medical University, Erbil, Iraq.
Department of Medical Genetics, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Biomed Pharmacother. 2021 Jul;139:111604. doi: 10.1016/j.biopha.2021.111604. Epub 2021 Apr 23.
NF-κB Interacting LncRNA (NKILA) is a long non-coding RNA (lncRNA) which has inhibitory roles on NF-κB. NF-κB regulates expression of several molecules participating in various crucial physiological reaction including immune responses, cell proliferation and differentiation, as well as cell death. Therefore, NKILA can be involved in the pathogenesis of a wide spectrum of human disorders. Numerous studies in hepatocellular carcinoma, breast cancer, melanoma, glioma and other types of neoplasms have indicated the role of NKILA in blockage of tumor growth and inhibition of metastasis. Further in vitro and in vivo assays including apoptosis assays, knock-down and knock-in experiments have verified such roles. In addition to its roles in neoplastic conditions, NKILA is involved in the pathogenesis of immune-related disorders. Dysregulation of expression of NKILA has been reported in patients with diverse conditions such as epilepsy, osteoarthritis, periodontitis and coronary artery disease. In this paper, we recapitulate the contribution of NKILA in neoplastic and non-neoplastic conditions.
NF-κB 相互作用的长非编码 RNA(NKILA)是一种长非编码 RNA(lncRNA),对 NF-κB 具有抑制作用。NF-κB 调节参与多种关键生理反应的几种分子的表达,包括免疫反应、细胞增殖和分化以及细胞死亡。因此,NKILA 可能参与广泛的人类疾病的发病机制。在肝癌、乳腺癌、黑色素瘤、神经胶质瘤和其他类型的肿瘤中进行的大量研究表明,NKILA 在阻止肿瘤生长和抑制转移方面发挥作用。进一步的体外和体内实验,包括凋亡实验、敲低和敲入实验,已经验证了这种作用。除了在肿瘤性疾病中的作用外,NKILA 还参与免疫相关疾病的发病机制。在患有各种疾病的患者中,如癫痫、骨关节炎、牙周炎和冠心病,已经报道了 NKILA 表达的失调。在本文中,我们总结了 NKILA 在肿瘤性和非肿瘤性疾病中的作用。